'Gp iib iiia' presentation slideshows

1.06k views • 92 slides

NSTEMI: GPIIB/IIIA Inhibitors & Emerging Antiplatelets : Where Do We Stand?

NSTEMI: GPIIB/IIIA Inhibitors & Emerging Antiplatelets : Where Do We Stand?. Rabih R. Azar , MD, MSc , FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University School of Medicine Beirut, Lebanon.

756 views • 50 slides

Gregg W. Stone MD for the ACUITY Investigators

Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes. Gregg W. Stone MD for the ACUITY Investigators.

609 views • 47 slides

Gregg W. Stone MD for the ACUITY Investigators

Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes. Gregg W. Stone MD for the ACUITY Investigators.

592 views • 47 slides

Hemostasis

Hemostasis. Hemostasis depends on the integrity of Blood vessels Platelets Coagulation factors Anticoagulation factors. Initial Laboratory Tests For Bleeding Abnormalities. Platelet count. Bleeding time. Partial thromboplastin time (PTT). Prothrombin time (PT). Thrombin time(TT).

548 views • 46 slides

Gregg W. Stone MD for the ACUITY Investigators

Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes. Gregg W. Stone MD for the ACUITY Investigators. Background: Current Management of ACS.

467 views • 46 slides

Coagulation Factor

Friction force. vWF. platelet. Coagulation Factor. platelet. platelet. fibrin. platelet. platelet. platelet. Antithrombotic pathway. Fibrinolytic pathway. contact Pathway. Tissue f. Pathway. TFPI. X. Protein C pathway. AT III pathway. V. Thrombin. Fibrinogen. FDP.

703 views • 43 slides

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients. Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper, Henry Smith, John Edmunds, Jay Varanasi and Tom Stuckey LeBauer Cardiovascular Research Foundation Greensboro, NC TCT 2009

433 views • 31 slides

New Horizons for Patients with ST-Elevation Myocardial Infarction

399 views • 27 slides

Gregg W. Stone MD for the ACUITY Investigators

Gregg W. Stone MD for the ACUITY Investigators. A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Disclosures. Gregg W. Stone Consultant to The Medicines Company and BMS Imaging

377 views • 22 slides

ASA Resistance and Clinical Outcomes

373 views • 21 slides

Harvey D. White on behalf of the ACUITY investigators

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation ACS Managed with an Invasive Strategy: Results from the Randomized ACUITY Trial. Harvey D. White on behalf of the ACUITY investigators.

318 views • 18 slides

Gregg W. Stone MD for the ACUITY Investigators

A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Gregg W. Stone MD for the ACUITY Investigators. Medical management. UFH/Enox + GP IIb/IIIa (n=4,603). PCI. Bivalirudin + GP IIb/IIIa (n=4,604).

250 views • 12 slides